Dr. Anthony Sabatelli, Partner at Dilworth IP will be presenting a free webinar entitled What is Patentable? Insight Into the New USPTO Guidance on Wednesday, May 21st from 1pm – 2pm EDT.  Interested parties should note that Dr. Sabatelli has been invited by the USPTO to present his comments in person on this Guidance on May 9th and he will relate his impressions on that forum to webinar participants.  Further details about the presentation can be found below.

Click here to Register for this presentation

About the Presentation
On March 4th the US Patent and Trademark Office issued guidelines to its examining corps for assessing patent eligible subject matter under 35 USC §101. The guidelines were issued in light of the Supreme Court’s decisions in Myriad, Prometheus, and related cases. See, “Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products.” The Guidance is intended to help examiners determine whether the subject matter of a patent claim is significantly different from what exists in nature.

  • So, what does this Guidance mean for the Biotech and Pharmaceutical Industry?
  • What strategies should patent attorneys employ to help their clients understand and navigate this recent development?
  • What do scientists and industry executives need to know?

This Webinar will address the impact of this Guidance on current patent practices, with particular emphasis on the Biotech and Pharmaceutical Industries. It will also:

  • Review the history that lead to the issuance of this Guidance.
  • Explain the three question inquiry and the multi-factor analysis set forth for determining whether a patent claim meets the criteria for p/?p=775&preview=trueatent eligibility under §101.
  • Discuss some of the specific examples of patent claims provided by the Guidance.
  • Propose practical strategies for drafting claims in view of the Guidance.
  • Provide an update from the US Patent and Trademark Office’s Public Forum being held on May 9th to solicit comment on the Guidance at which Dr. Sabatelli will have provided his feedback.


Dilworth IP is an intellectual property and business law firm providing legal services in the areas of patent and trademark prosecution, opinions, agreements and litigation in the chemical, biotech, pharmaceutical, medical device, material science, consumer products, electronics, software, and semiconductor industries. We’ve been in the lab. Whether your invention is a controlled-release pharmaceutical, a fuel cell, or a new polyolefin catalyst, our attorneys will speak your language and listen well. We’ll quickly grasp nuances of your complex technology and capture the IP protection you deserve. To learn more about the firm, please visit www.dilworthip.com.